NCT00355355 is a Phase 3 clinical trial of Talaporfin sodium in Carcinoma, Hepatocellular, sponsored by Light Sciences Oncology.

Who is sponsoring NCT00355355?

NCT00355355 is sponsored by Light Sciences Oncology.

What drugs are being tested in NCT00355355?

Interventions in NCT00355355: Talaporfin sodium, Interstitial Light Emitting Diodes, Percutaneous placement of device in the liver, Standard Care.

What condition does NCT00355355 study?

NCT00355355 studies Carcinoma, Hepatocellular, Liver Neoplasms.

Is NCT00355355 still recruiting?

NCT00355355 is currently completed. Last updated 22 January 2015.

Last reviewed 2015-01-22 · How we verify

NCT00355355

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 3 Randomized Study to Evaluate Survival of Patients Treated With Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) as Compared to the Standard of Care Therapies in the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

Completed Phase 3 Last updated 22 January 2015

What this trial tests

Phase 3 trial testing Talaporfin sodium in Carcinoma, Hepatocellular in 208 participants. Completed in 1 September 2012.

Timeline

1 July 2006

Primary endpoint
1 September 2012

1 September 2012

Quick facts

Lead sponsor	Light Sciences Oncology
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	208
Start date	1 July 2006
Primary completion	1 September 2012
Estimated completion	1 September 2012
Sites	34 locations across Croatia, Hong Kong, India, Malaysia, Philippines, Poland, Serbia, Singapore

Drugs / interventions tested

Talaporfin sodium — full drug profile →
Interstitial Light Emitting Diodes
Percutaneous placement of device in the liver
Standard Care — full drug profile →

Conditions studied

Carcinoma, Hepatocellular — all drugs for Carcinoma, Hepatocellular →
Liver Neoplasms — all drugs for Liver Neoplasms →

Sponsor

Light Sciences Oncology — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Hepatocellular or Liver Neoplasms. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Overall survival
Time frame: 130 weeks

Sponsor's own description

The purpose of the study is to assess the survival of patients treated with Litx™ versus standard of care therapies in the treatment of unresectable hepatocellular carcinoma (HCC), and to demonstrate the safety of Litx™ therapy. Litx™ consists of a light-activated drug, talaporfin sodium (LS11, Light Sciences Oncology, Bellevue, Washington), and a light generating device, composed of light-emitting diodes (LEDs), that is energized by a power controller and percutaneously placed in the target tissue inside the body.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radiofrequency ablation: mechanisms and clinical applications.
Wu J, Zhou Z, Huang Y, Deng X, et al · · 2024 · cited 24× · PMID 39359691 · DOI 10.1002/mco2.746

Verify or expand the search:

Other recruiting trials for Carcinoma, Hepatocellular

Currently open trials in the same condition.

NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT06742892 — A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to · Phase 2 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06349980 — A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00355355 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Light Sciences Oncology
Last refreshed: 22 January 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00355355.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing